ABG WTT-MedAvail Ltd - 13 Mar 2023 Form 4 Insider Report for MedAvail Holdings, Inc.

Role
10%+ Owner
Signature
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner By: /s/ Fan Yu, Director
Issuer symbol
N/A
Transactions as of
13 Mar 2023
Net transactions value
+$2,499,999
Form type
4
Filing time
15 Mar 2023, 16:30:12 UTC
Previous filing
06 Apr 2022
Next filing
21 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDVL Pre-Funded Warrant (Right to Buy) Purchase $2,190,000 +6,818,181 $0.3212 6,818,181 13 Mar 2023 Common Stock 6,818,181 $0.001000 See footnote F1, F2, F3
transaction MDVL Pre-Funded Warrant (Right to Buy) Purchase $310,000 +965,130 $0.3212 965,130 13 Mar 2023 Common Stock 965,130 $0.001000 See footnote F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023.
F2 The Pre-Funded Warrants do not expire.
F3 These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
F4 These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.